Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you make the most of staying home.
Visit the hub

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland, on Jan. 30, 2020.

Arnd Wiegmann/Reuters

Britain is in talks with Swiss drugmaker Roche Holding AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States which have already given preliminary approval to the tests.

Mass antibody testing with millions of kits is being considered by many countries as a way to speed the reopening of economies devastated by lockdowns and to introduce more tailored social distancing measures.

Tests carried out by Public Health England at Porton Down, a laboratory that provides sensitive and specialist scientific services to the government, concluded on May 7 that the Roche test detected the exact antibodies prompted by the virus. The findings were only made public late on Wednesday.

Story continues below advertisement

“This is a good test that will stand us in good stead, moving forwards, and I think it will be incredibly important as the days, weeks and months go by,” said Jonathan Van-Tam, the government’s deputy chief medical officer.

“I anticipate that it will be rapidly rolled out in the days and weeks to come, as soon as it is practical to do so. I also anticipate that the focus will be on the National Health Service and on carers in the first instance,” he told a news briefing.

Van-Tam cautioned, however, that scientists still had limited understanding of whether antibodies provided immunity, to what extent and for how long.

A spokesman for Prime Minister Boris Johnson said the test was an important breakthrough which had the potential to be a game-changer.

The spokesman said there was the possibility of issuing some kind of certificate based on immunity but that scientists still needed to know more about that subject area.

The Roche test received a conformity assessment, known as Conformité Européenne, or CE mark, from the European Union on April 28 and received Emergency Use Authorization from the U.S. Food and Drug Administration on May 2.

Roche said it was able to produce hundreds of thousands of the tests per week for the United Kingdom. Germany is getting 3 million of them this month, and 5 million a month after June.

Story continues below advertisement

The Daily Telegraph newspaper, which first reported the findings, said the government was in negotiations with Roche to buy millions of kits.

‘VERY EXCITING’

Transport Minister Grant Shapps was asked at the government’s daily news briefing whether there was any exclusive deal between Roche and the United Kingdom.

“Of course we’ll want to get as many tests as possible – we’ve never restricted ourselves with that regard,” Shapps said, describing the approval of the Roche test as “very exciting.”

The antibody tests – also known as a serology test – show who has been infected, although it is not yet clear whether the presence of antibodies to the new coronavirus, SARS-CoV-2, confers permanent immunity.

They require a blood test that can be run on fully-automated equipment in laboratories to provide results in just 18 minutes.

Britain’s health ministry did not answer questions about how many tests it would order.

Story continues below advertisement

“We are exploring the use of antibody testing across the NHS and ultimately the wider public,” a ministry spokesman said, adding that the government was “actively working on our plans for rolling out antibody testing.”

Similar antibody tests have also been developed by companies including U.S.-based Abbott Laboratories and Italy’s DiaSorin. Abbott and Germany’s Siemens Healthineers have separately laid out plans to produce 20 million tests or more per month for the global market from June.

Based in Basel, Switzerland, Roche said it is ramping up capacity to produce high double-digit millions of tests per month to serve countries accepting the CE mark and the United States.

Switzerland is nonetheless circumspect about the value of antibody testing in helping craft a strategy to ease restrictions.

Instead, Switzerland is counting on a plan that includes trimming new infections to manageable levels, testing everybody who is symptomatic for active infections, and rigorous contact tracing to find those who may have come into contact with infected individuals.

“The government up to now has not bought any antibody tests,” a Federal Health Ministry spokesman told Reuters. “Their ability to inform us remains simply too uncertain for them to be part of an easing strategy.”

Story continues below advertisement

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies